Another reason this could help is by allowing the access to quality drug medications by the 5 R’s which are, “The RIGHT diagnosis at the RIGHT time, and the RIGHT medication, in the RIGHT dosage over a period of time that is RIGHT for that patient.” (J. Jones) In order to make sure of better patient outcomes. Here are a few more strategies that I would implement:
~Exclusion of specific drugs or drug classes from coverage- Some drugs that were previously excluded are now covered but placed in a coverage category with a really hefty copayment, or are covered only under prior authorizations, or as part of a type of utilization management program. In other cases drugs may be covered only for certain categories of patients such as growth hormones where there is documentation that a child has a medical syndrome causing him or her to grow too slowly, or in association with certain programs like appetite suppressants for a patient who meets with a nutritionist on a regular basis
~Exclusion of over-the-counter drugs from coverage- Cost tradeoffs can sometimes create a rationale for covering an OTC drug. If a plan covers prescription pain medications, but does not cover aspirin or ibuprofen, it’s harder for me as a PBM to recommend a substitution on a medicine that is a nonprescription medication. Let’s take aspirin for example, the total cost might be lower than the copayment on an expensive alternative like a Cox-2 inhibitor. But in cases like Claritin, the cost of the OTC drug is much higher; as a matter of fact, it may be cheaper for a
References: Jones, J.D. (2003). Developing an effective generic prescription drug program. Benefits Quarterly, 19(1): 14-18. Retrieved from Proquest. Searles, A., Jeffreys, S., Doran, E., & Henry, D. (2007, Aug.). Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. Medical Journal of Australia, 187(4), 236-239. Retrieved from Proquest. Sica, J. (2001). Prescription Drug Coverage and Control. Employee Benefit Issues: The Multiemployer Perspective, 43: 312-324. Retrieved on Dec. 22,2012 from www.amcp.org